Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMR001
- Development stage
- Phase 3
- Lead developer
- 未名生物医药
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Ophthalmic, Topical
01
Overview
SMR001 is a recombinant human nerve growth factor (rhNGF) developed as an ophthalmic solution for the treatment of moderate to severe dry eye disease and also investigated for diabetic foot ulcers. The drug is designed to promote corneal nerve regeneration and improve ocular surface health by mimicking endogenous nerve growth factor activity. Clinical studies have evaluated its safety, tolerability, pharmacokinetics, and efficacy in both healthy volunteers and patients with dry eye disease[1][8]. The mechanism of action involves supporting neuronal survival and regeneration at the ocular surface.
- Other names
- recombinant human nerve growth factorrhNGF
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NGFR (p75NTR)
Beyond the preview
Go deeper on SMR001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMR001.